本周ACX社区开放讨论主题广泛，涵盖Alpha School的评论、FDA监管经验交流等。关于Alpha School，讨论了其教育模式、学生体验及与传统精英学校的对比。同时，文章还征集了在FDA监管方面有经验的人士，希望他们能为生命科学实验室生成合规文档的工具提供反馈。讨论中既有对Alpha School的积极评价，也有对其招生政策和学生流失率的质疑，反映了社区成员对教育、监管等话题的多元观点。

🏫 Alpha School的讨论：文章引用了关于Alpha School的评论，包括对其教育模式的积极和消极评价，以及对“Bloom's Two Sigma”理论的质疑。其中，Redditors的评论多为负面，而ACX评论者的评价则相对积极。

🤔 Alpha School的争议：文章探讨了Alpha School的招生政策和学生流失率问题。一位Alpha School的员工声称学校录取所有能支付4万美元学费的学生，但一位家长指出，2022年入学的来自Brownsville校区的低收入学生中，85%已经离开学校。

💡 Alpha School的优势与比较：尽管存在争议，文章认为Alpha School的表现似乎优于其他精英私立学校。作者引用了Phil H的观点，将Alpha School的现象与“美国正在重新发明中国”联系起来，并提到了selection bias（选择偏差）的可能性。

🔬 FDA监管经验征集：文章还提到了一个项目，该项目旨在帮助生命科学实验室生成符合FDA要求的文档。项目组正在寻找具有FDA监管经验的人士，以获取关于监管工作的实际痛点反馈，用于改进其工具。

This is the weekly visible open thread. Post about anything you want, ask random questions, whatever. ACX has an unofficial subreddit, Discord, and bulletin board, and in-person meetups around the world. Most content is free, some is subscriber only; you can subscribe here. Also:

1: Good comments on the Alpha School review:

Michael Pershan challenges the “Bloom’s Two Sigma” claim.

Alpha School experiences from Redditors, mostly negative (1, 2, beware stereotypical Redditors who hate everything they can associate with “tech bros” but there’s some signal to be found in the noise).

Alpha School experiences from ACX commenters, mostly positive (1, 2, 3, 4, 5)

Some good comments from Pamela Hobart and Matt Bateman, who work at Alpha School, CTRL+F their names for more.

Most people agree that it’s easy for any home school to teach the whole curriculum in two hours. Shouldn’t this be a bigger deal? Also, how come nobody has tried creating a school that actually only goes two hours a day and costs one-quarter as much?

Is it selection bias? An employee says they admit everyone (…who can pay the $40K tuition!) But an Alpha parent claims that “85% of the low SES students from the Brownsville Campus that started at the school in 2022 are no longer there and its not due to lack of motivation or ability” (more details deeper in the thread, but I still don’t feel like I get a good explanation what happened to them). I think the strongest argument is that they seem to do better than other elite private schools, so even assuming an equal level of selection bias they still look good.

Phil H: “From where I'm standing, it's very much like Americans are kind of reinventing China but with less tears.” (see also MKBA)

2: A reader is looking to speak with people who have FDA regulatory experience (regulatory affairs, quality assurance, etc.) for a project. They are building a tool to help life science labs generate compliant documentation for submissions like INDs or 510(k)s, and want to get feedback from experts on the real-world pain points of regulatory work. If you have this background and are open to a brief chat, please contact at ankit@clioapp.ai